The study of the state of pharmaceutical provision for patients with cardiovascular diseases using ABC- and VEN-analyses




complex ABC/VEN analysis, medicines, cardiovascular diseases, government program, pharmacoeconomics


Aim. To assess the state of pharmaceutical provision for patients with cardiovascular diseases (CVD) using ABC, VEN and complex ABC/VEN analyses.

Materials and methods. The study was performed according to the data of the medical records of outpatients who were registered in the Public Health Institution (PSI) “Kharkiv City Clinical Hospital No. 27”. The methods of ABC, VEN and complex ABC/VEN analysis were used.

Results and discussion. The results of the study using the ABC-analysis method allowed us to determine that the largest number of drugs was in the group C, which included 25 drugs, or 51.02 % of the total number of prescriptions. During the VEN analysis it was found that the vast majority of drugs (41 drugs) belong to the group V – vital essential medicines. The complex ABC/VEN analysis showed that drugs with the A/V status (the most costly and vital essential medicines) had the highest percentage (32.20 %) of the total consumption. It should be separately noted that the A/N group (the most costly and nonessential medicines) took the second position by percentage after the A/V group. A high percentage (31.05 %) in the A/N group is explained by the fact that the group includes the drug Magnikor, which has the highest frequency of prescription although this drug is not included in the National List of Essential Medicines (NLEM) and in the “Available medicines” program.

Conclusions. The results of the studies of the state of pharmaceutical care for patients with CVD make it possible to draw attention to the urgency of the problems of drug availability to the population, namely expanding the list of medicines that are reimbursed in the framework of the government programs, in particular by including the drug Magnikor in the “Available medicines” program.

Author Biographies

A. S. Nemchenko, National University of Pharmacy

Doctor of Pharmacy (Dr. habil.), head of the Organization and Economy of Pharmacy Department

V. N. Nazarkina, National University of Pharmacy

Candidate of Pharmacy (Ph.D.), associate professor of the Organization and Economу of Pharmacy Department

Yu. Ye. Kurylenko, National University of Pharmacy

Postgraduate student of the Organization and Economy of Pharmacy Department


European Cardiovascular Disease Statistics.(2017). Retrieved from:

Dostupniliky. [Available medicines]. Retrieved from:

Reiestr optovo-vidpusknykh tsinnalikarskizasoby MOZ Ukrainy. Retrieved from:

Ofitsiinyi sait Kabinetu ministriv Ukrainy. Retrieved from:

Bezditko, N. V., Chynush, I. V. (2012). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 4 (24), 54–59.

Vorobev, P.A. (2008). Ratcionalnaia farmakoterapiia, 1 (10), 5–14.

Morozov, A. M., Yakovlieva, L. V., Bezditko, N. V., Mishchenko, O. Ya., Stepanenko, A. V., Zimenkovskyi, A. B., Parii, V. D., Chynush, I. V. (2013). Otsinka klinichnoi ta ekonomichnoi dotsilnosti vykorystannia likarskykh zasobiv u likuvalno–profilaktychnomu zakladi (suprovid formuliarnoi systemy): metodychni rekomendatsii. Kiev, 36.

ASHP Guidelines on Medication Cost Management Strategies for Hospitals and Health Systems. (2008). American Journal of Health-System Pharmacy, 65(14), 1368–1384.






Organization and Economy of Pharmacy